Neurolytic Healthcare

Neurolytic Healthcare, commonly branded as Mable, is a private digital health and precision-medicine company focused on neurological conditions, initially centered on migraine care. The company combines genetic data, biomarkers, and software-driven clinical decision support to help match patients to more appropriate therapies and improve treatment selection. Its offerings have been described as digitally and genomically driven medical devices, including a diagnostic support tool, a pharmacogenetic test, and a mobile application for migraine event prediction. Neurolytic Healthcare appears to operate as an active U.S.-focused business under the Mable brand, although its original UK entity, Neurolytic Healthcare Ltd, was dissolved in 2023. The business is more healthtech/diagnostics/telehealth oriented than a traditional therapeutics developer, and no conventional drug-development pipeline is publicly evident.